Vaxcyte GAAP EPS of -$1.56 misses by $0.25
Source: SeekingAlpha
2025-11-04 17:23:31 ET
More on Vaxcyte
- Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript
- ClearBridge SMID Cap Growth Strategy adds CRDO, RKLB, exits OSCR, RARE
- Vaxcyte teams up with Thermo Fisher to ensure future vaccine production
- Seeking Alpha’s Quant Rating on Vaxcyte
- Historical earnings data for Vaxcyte
Read the full article on Seeking Alpha
For further details see:
Vaxcyte GAAP EPS of -$1.56 misses by $0.25
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
0.36% G/L:
$58.38 Last:
341,094 Volume:
$58 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
